SYGNIS AG

euro adhoc: LION bioscience AG
Management Changes
LION bioscience AG expands Management Board after successful acquisition of SYGNIS Bioscience GmbH & Co. KG

-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- 09.10.2006 Heidelberg, October 9, 2006 - After successful completion of the capital increase in connection with the acquisition of SYGNIS Bioscience GmbH & Co. KG, the Supervisory Board of LION bioscience AG today appointed Dr. Alfred Bach to the Management Board with effect of October 10, 2006. Up to now Dr. Alfred Bach was CEO of Axaron Bioscience AG, a drug developing company in the field of CNS (central nervous system). Dr. Alfred Bach will serve as CEO, and Peter Willinger as CFO of LION bioscience AG. The acquisition of all the shares in SYGNIS Bioscience GmbH & Co. KG, as announced in July 2006, was now successfully completed with registration in the commercial register. Following the acquisition of SYGNIS Bioscience GmbH & Co. KG, the share capital of LION bioscience AG was increased by Euro 7.807.535 from Euro 19.870.175 to Euro 27.677.710. Lion bioscience AG will present the next steps for future development on the annual shareholders' meeting for fiscal year 2005/2006 on November 28, 2006 in Eppelheim. ### Except for the historical information contained herein, the matters set forth in this press release are forward looking. These forward-looking statements may include projections, assumptions, estimates, targets, and descriptions of future events. Such statements are based on currently available information and on LION's current expectations as to future events that may not prove to be accurate. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Many factors could cause the actual results, performance or achievements of LION to be materially different from those that may be projected, expected, targeted, expressed or implied by such statements. All roll-out plans and future dates with respect to completion of development and market release of LION products are target dates only based on the company's current planning and may change in the future. Any delays in the current product release schedule will have a materially adverse effect on the company's targets for fiscal year. ### end of announcement euro adhoc 09.10.2006 17:31:15 -------------------------------------------------------------------------------- ots Originaltext: LION Bioscience AG Im Internet recherchierbar: http://www.presseportal.de Further inquiry note: Peter Willinger Vorstand Finanzen Telefon: +49(0)6221 4038 293 E-Mail: peter.willinger@lionbioscience.com Branche: Biotechnology ISIN: DE0005043509 WKN: 504350 Index: CDAX, Prime All Share, Technologie All Share Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime standard New York / ADR Börse Berlin-Bremen / free trade Hamburger Wertpapierbörse / free trade Baden-Württembergische Wertpapierbörse / free trade Börse Düsseldorf / free trade Niedersächsische Börse zu Hannover / free trade Bayerische Börse / free trade

Das könnte Sie auch interessieren: